Sein CANTO (Paris) A Cohort to Quantify and to Predict Treatment Related Chronic Toxicities in Patients With Non-metastatic Breast Cancer. Paris PAUL-HENRI COTTU
Phases précoces tumeurs solides CA009-002 (Immuno) A Phase 1/2a Dose Escalation and Cohort Expansion Study for Safety, Tolerability, and Efficacy;of anti-GITR Monoclonal Antibody (BMS-986156) Administered Alone and in Combination;with Nivolumab (BMS-936558, anti PD-1 Monoclonal Antibody) in Advanced Solid Tumors Paris EMANUELA ROMANO
Phases précoces tumeurs solides CA017-003 A Phase 1/2a Study of BMS-986205 Administered in Combination With Nivolumab (Anti-PD-1 Monoclonal Antibody) and in Combination With Both Nivolumab and Ipilimumab (Anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors. Paris CHRISTOPHE LE TOURNEAU
Sein CirCA 01 - IC 2014-05 Circulating Tumor DNA and Follow-up of BRCA1 Mutation Carriers (CirCa 01). Paris JEAN-YVES PIERGA
Gynécologie - Ovaires PiSARRO p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin/Pegylated Liposomal Doxorubicin Combination Chemotherapy With or Without APR-246. Paris PAUL-HENRI COTTU
Sein métastatique RH+ SAFIR PI3K A Phase II Randomized Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy as Maintenance Therapy in Patients With PIK3CA Mutated Advanced Breast Cancer Paris, Saint-Cloud
Sein métastatique RH+ SAFIR-TOR Identification of the Molecular Alterations Associated With Resistance to Endocrine Therapy and Impacting Treatment With mTOR Inhibitor of HR+ Metastatic Breast Cancer in Post-menopausal Women. Paris, Saint-Cloud PAUL-HENRI COTTU
Mélanome uvéal et tumeurs oculaires IMCgp100-202 A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma Paris
Appareil Digestif SCARCE (C17-02 PRODIGE 60) A Non-comparative Randomized 2:1 Phase II Study of Docetaxel, Cisplatin, and 5-fluorouracil in Combination or Not With Atezolizumab in Patients With Metastatic or Unresectable Locally Advanced Squamous Cell Anal Carcinoma Paris
Sein métastatique RH+ XENERA-1 (BI 1280-0022) A multi-centre, double-blind, placebo-controlled,randomised phase II trial to compare efficacy of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in post-menopausal women with HR+ / HER2- metastatic breast cancer and non-visceral disease Paris